A naukri.com initiative
Bioengineer
1w
400
Image Credit: Bioengineer
University of Houston Secures $3M Grant to Establish Cutting-Edge Cancer Biomarker Facility for Advancing Immunotherapy Research
- The University of Houston has established the Cancer Immunotherapy Biomarker Core (CIBC) with a $3 million grant from CPRIT to advance cancer research and immunotherapy.
- The initiative focuses on biomarker discovery, expanding research infrastructure in Texas, and enhancing personalized cancer treatment.
- Using targeted proteomics, the UH CIBC can analyze over 11,000 proteins simultaneously in body fluid samples, aiding early cancer detection and precise immunotherapy.
- The core facility also features a 21,000-plex protein array platform for analyzing autoantibodies and immune system responses in cancer.
- Immunotherapy harnesses the immune system to target cancer cells specifically, reducing collateral damage to healthy tissues but relies on biomarkers for effectiveness.
- Dr. Chandra Mohan highlights the importance of refined biomarkers for early cancer detection, accurate prognosis, and treatment monitoring.
- Immunologist Dr. Weiyi Peng complements the core by studying T cell-mediated anti-tumor immune responses, fostering interdisciplinary innovation at UH.
- The UH CIBC aims to democratize advanced proteomic platforms in Texas, offering subsidized services to accelerate cancer immunotherapy research.
- In addition to screening services, the core provides educational workshops to familiarize researchers with contemporary proteomic methodologies.
- The facility's sophisticated platforms enable precise quantification of protein biomarkers and high-throughput screening of antibody binding interactions.
Read Full Article
24 Likes
For uninterrupted reading, download the app